GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene SA (XPAR:TNG) » Definitions » Cyclically Adjusted PS Ratio

Transgene (XPAR:TNG) Cyclically Adjusted PS Ratio : 26.00 (As of Jun. 05, 2024)


View and export this data going back to 1998. Start your Free Trial

What is Transgene Cyclically Adjusted PS Ratio?

As of today (2024-06-05), Transgene's current share price is €1.30. Transgene's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec23 was €0.05. Transgene's Cyclically Adjusted PS Ratio for today is 26.00.

The historical rank and industry rank for Transgene's Cyclically Adjusted PS Ratio or its related term are showing as below:

XPAR:TNG' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 5.53   Med: 15.26   Max: 43.36
Current: 24.57

During the past 13 years, Transgene's highest Cyclically Adjusted PS Ratio was 43.36. The lowest was 5.53. And the median was 15.26.

XPAR:TNG's Cyclically Adjusted PS Ratio is ranked worse than
85.52% of 504 companies
in the Biotechnology industry
Industry Median: 5.525 vs XPAR:TNG: 24.57

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Transgene's adjusted revenue per share data of for the fiscal year that ended in Dec23 was €0.012. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €0.05 for the trailing ten years ended in Dec23.

Shiller PE for Stocks: The True Measure of Stock Valuation


Transgene Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Transgene's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transgene Cyclically Adjusted PS Ratio Chart

Transgene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.39 22.26 37.42 27.18 27.15

Transgene Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.42 - 27.18 - 27.15

Competitive Comparison of Transgene's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Transgene's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Transgene's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transgene's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Transgene's Cyclically Adjusted PS Ratio falls into.



Transgene Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Transgene's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1.30/0.05
=26.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Transgene's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec23 is calculated as:

For example, Transgene's adjusted Revenue per Share data for the fiscal year that ended in Dec23 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec23 (Change)*Current CPI (Dec23)
=0.012/118.3900*118.3900
=0.012

Current CPI (Dec23) = 118.3900.

Transgene Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201412 0.046 99.860 0.055
201512 0.037 100.040 0.044
201612 0.041 100.650 0.048
201712 0.033 101.850 0.038
201812 0.021 103.470 0.024
201912 0.080 104.980 0.090
202012 0.036 104.960 0.041
202112 0.110 107.850 0.121
202212 0.031 114.160 0.032
202312 0.012 118.390 0.012

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Transgene  (XPAR:TNG) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Transgene Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Transgene's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Transgene (XPAR:TNG) Business Description

Industry
Traded in Other Exchanges
Address
400 Boulevard Gonthier d’Andernach, Parc d’Innovation - CS80166, Illkirch-Graffenstaden, FRA, 67400
Transgene SA is a biotechnology company. It is involved in the business of discovering and focusing immune-targeted therapies for the treatment of cancer and infectious diseases. The company's clinical-stage programs are TG4010 for non-small cell lung cancer and Pexa-vec for liver cancer. Its product pipeline includes TG4001, TG1050, TG6002 etc. It is engaged in clinical research and development of therapeutic vaccines and immunotherapeutic products.

Transgene (XPAR:TNG) Headlines

No Headlines